NCT03361852 — Dana-Farber Cancer Institute neoantigen vaccine trial
Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma
Registry record
| Registry ID | NCT03361852 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Follicular Lymphoma |
| Enrollment | 20 participants (target) |
| Start date | 2022-03-14 |
| Primary completion | 2026-12-31 (est.) |
| Last registry update | 25 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03361852), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT03361852?
NCT03361852 (Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT03361852 recruiting?
As of the 2026-03-25 registry update, NCT03361852 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03361852?
The lead sponsor is Dana-Farber Cancer Institute.
What condition does NCT03361852 study?
The registered condition is Follicular Lymphoma. Primary completion is listed as 2026-12-31 (estimated).
Are results available for NCT03361852?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03361852.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.